Entero Therapeutics (NASDAQ:GRDX) Issues Quarterly Earnings Results

Entero Therapeutics (NASDAQ:GRDX) reported quarterly results Wednesday, posting EPS of -$0.82 and revenue of $0.04 million, according to FiscalAI. The stock opened at $4.61; shares have a 1-year range of $1.06–$5.84 and a market cap of $15.49 million. DRW Securities LLC bought 48,623 shares (~$227,000) in Q4, per the company’s SEC filing.

Original reporting
Published May 27, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Entero Therapeutics (NASDAQ:GRDX) Issues Quarterly Earnings Results — source image
Decision brief

The 30-second read

$GRDXBearishMed
01

Why it matters

The earnings release confirms continued operating losses and extremely low quarterly revenue, which can pressure sentiment and liquidity premiums; the disclosed new institutional position may reduce downside volatility but is unlikely to change the fundamental risk profile without pipeline or financing updates.

02

Market read

For GRDX, the tradable catalyst is the earnings datapoint (negative EPS, minimal revenue) with a secondary sentiment factor from institutional buying.

03

What to watch

No details on cash burn, balance-sheet runway, or trial progress were provided; those can outweigh headline EPS/revenue for microcap biotech traders.

Relevance 8/10Timing: Immediate (reported quarterly results on Wednesday; potential same-day/next-session repricing).

Background

Entero Therapeutics is a clinical-stage biopharmaceutical company developing targeted oral therapies for gastrointestinal diseases, including latiglutenase (Phase 2) and capeserod (Phase 1).

Company-level read

Ticker impact

$GRDXBearishMedium confidence
Context

Entero Therapeutics reported quarterly EPS of ($0.82) and revenue of $0.04M, alongside a new hedge-fund stake disclosure.

Expected impact

Likely choppy to downside-biased reaction unless investors focus on the institutional buying as a sentiment offset.

Evidence & confidence

The article provides hard earnings figures (negative EPS, very low revenue) and only a modest institutional stake size; without guidance or trial readouts, the earnings datapoint dominates.

Market effects

Clinical-stage GI biopharma names may see muted read-through because the article lacks pipeline efficacy or regulatory catalysts.

Primarily impacts US small-cap biotech sentiment; limited spillover expected beyond similar microcaps.

Low—no international regulatory, trial, or commercialization developments mentioned.

Counterpoint

Institutional accumulation (DRW stake) could indicate perceived valuation dislocation or upcoming catalysts not covered in this brief, supporting a mean-reversion bid.

Key entities

  • Entero Therapeutics

    Reported quarterly EPS of ($0.82) and revenue of $0.04M; disclosed new institutional ownership via SEC filing.

  • DRW Securities LLC

    Purchased 48,623 shares (~$227,000) and held 1.45% as of its most recent SEC filing.

Related articles

$GRDXMedAI 8/10

GridAI to Acquire Pronghorn for 66 Million Common-Equivalent Shares

GridAI Technologies agreed to acquire Pronghorn Resources for 66 million common-equivalent shares, with the deal expected to close by November 23, 2026. Pronghorn will become a subsidiary of GridAI. Additionally, GridAI plans to assume Sigma9 Capital's rights in a Wyoming nuclear joint venture in exchange for common and preferred shares.

$GRDXMed

GridAI Technologies Corp. (GRDX): Completion of Acquisition or Disposition of Assets

GridAI Technologies Corp. (GRDX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 GridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027 • Built on approximately $1.7 billion in historica

$GRDXMed

GridAI Technologies Corp. (GRDX) to Acquire Pronghorn for 1.25M Shares

GridAI Technologies (GRDX) agreed to acquire Pronghorn Resources for 1.25M common shares and up to 129.5K preferred shares, pending approvals. Pronghorn has 100M cubic feet of daily gas production and 1M acres of mineral interests. GridAI aims to deliver 300 MW of power by 2027, targeting Wyoming's AI data center market. Closing is expected by November 22, 2026.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.